in their recent analysis; these authors advocate for pCR as a predictive biomarker of event free survival in HER2+ breast cancer (HR: 0.32, 95% CI: 0.21–0.47), albeit in the setting of modest pCR rates of 36.4%. Here, ERBB2 is linked to breast cancer.